Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Random

Display 15 Products per page

Xtandi
Read More
Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits binding of the androgens to the AR, inhibits AR nuclear translocation, and inhibits association of the AR with DNA.
January 18, 2018
Find out more
Mekinist
Read More
Mekinist (trametinib; Novartis/Japan Tobacco) is a selective allosteric inhibitor of the MEK1 and MEK2 enzymes in the mitogen-activated protein kinase (MAPK) pathway.
August 30, 2018
Find out more
Inbrija
Read More
Inbrija (Acorda Therapeutics) is an inhaled formulation of levodopa, in development as an adjunct to existing oral levodopa formulations in patients experiencing motor fluctuations.
June 21, 2018
Find out more
Utibron Neohaler
Read More
Novartis, under license from Vectura and Sosei, developed Utibron, a once-daily long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combination product containing indacaterol and glycopyrrolate.
July 31, 2018
Find out more
Bococizumab
Read More
Bococizumab is an antidyslipidemic humanized antibody that inhibits PCSK9. PCSK9 is a protease involved in the intracellular and extracellular regulation of LDL receptor (LDLR) expression…
June 29, 2016
Find out more
NeoRecormon
Read More
NeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in chronic kidney disease (CKD).
January 11, 2018
Find out more
Daliresp
Read More
Daliresp (roflumilast; AstraZeneca/Allergan/Takeda) is an oral phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of patients with severe chronic obstructive pulmonary disease (COPD), who suffer from chronic bronchitis and frequent exacerbations.
July 31, 2018
Find out more
Ocrevus
Read More
Ocrevus is a second-generation cluster of differentiation (CD)20 antibody. Similar to Roche’s blockbuster cancer drug Rituxan (rituximab), Ocrevus specifically targets CD20+ B cells, thus depleting lymphocytes that produce the autoimmune response.
November 24, 2017
Find out more
Valoctocogene Roxaparvovec
Read More
Valoctocogene roxaparvovec (BioMarin), also known as valrox, is an adeno-associated virus-mediated gene therapy that delivers human B domain-deleted coagulation factor VIII (fVIII) to patients with hemophilia A.
May 20, 2018
Find out more
Ixempra
Read More
Ixempra (ixabepilone; R-Pharm/Otsuka) is a lactam analog of epothilone B that binds to microtubules via tubulin.
February 4, 2016
Find out more
Ocaliva
Read More
Ocaliva (obeticholic acid; Intercept Pharmaceuticals) is a selective farnesoid X receptor (FXR) agonist. FXR is a nuclear bile acid receptor involved in the regulation of bile acids, lipids, and possibly glucose. Ocaliva is a derivative of chenodeoxycholic acid, the endogenous FXR agonist found naturally in human bile acid. By activating FXR, Ocaliva improves insulin sensitivity and inhibits lipogenesis, which reduces fat buildup in the liver and results in decreased inflammation. Ocaliva has also been linked to weight loss. Ocaliva is currently approved in the US and EU for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
July 22, 2019
Find out more
Crestor
Read More
Crestor (rosuvastatin calcium; AstraZeneca/AbbVie/Shionogi) is a member of the statin class of antidyslipidemic drugs, which competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG Co-A) reductase.
June 22, 2018
Find out more
Stalevo
Read More
Stalevo (Novartis/Orion), indicated for the treatment of Parkinson’s disease patients with end-of-dose wearing-off symptoms, contains a combination of the catechol-O-methyltransferase (COMT) inhibitor entacapone, levodopa, and an AADC inhibitor (carbidopa).
June 21, 2018
Find out more
Zydelig
Read More
Zydelig (idelalisib; Gilead) is an oral, highly selective inhibitor of the phosphoinositide 3-kinase (PI3K) isoform p110-delta. In vitro studies have demonstrated that Zydelig results in decreased phosphorylation Akt and other downstream effectors, an increase in poly (ADP-ribose) polymerase and caspase cleavage, and an induction of apoptosis.
January 31, 2019
Find out more
Ygalo
Read More
Ygalo (melphalan-flufenamide; Oncopeptides) is a cytotoxic alkylating agent that consists of melphalan conjugated to phenylalanine
August 9, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *